Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2010

01-06-2010 | Case Report

Regression of B-Cell Lymphoma of the Liver with Hepatitis C Virus Infection After Treatment with Pegylated Interferon-α and Ribavirin

Authors: Yayoi Oda, Tadayuki Kou, Masaki Watanabe, Yojiro Sakuma, Nori Taguchi, Yoko Kato, Yasushi Kudo, Atsushi Yamauchi, Yasushi Sugiura, Shinya Ohashi, Masanori Asada, Toyokazu Fukunaga, Kiyotaka Kawaguchi, Hiroaki Ito, Takefumi Nakamura, Shujiro Yazumi

Published in: Digestive Diseases and Sciences | Issue 6/2010

Login to get access

Excerpt

The pathogenesis of human B-cell lymphoma is not well understood, although some types of B-cell lymphoma seem to be related to infection with pathogens such as Helicobacter pylori [1]. Accumulating evidence reveals a high incidence of B-cell lymphoma in patients with hepatitis C virus (HCV) infection, suggesting a link between HCV infection and the development of B-cell lymphoma [2‐6]. …
Literature
1.
2.
De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood. 1997;90:776–782.PubMed
3.
Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127:423–428.PubMed
4.
Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003;102:996–999.CrossRefPubMed
5.
Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125:1723–1732.CrossRefPubMed
6.
Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010–2017.CrossRefPubMed
7.
Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034–3044.CrossRefPubMed
8.
Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–577.CrossRefPubMed
9.
10.
Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: result of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131:1879–1886.CrossRefPubMed
11.
Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Patho. 2007;60:1378–1383.CrossRef
12.
Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89–94.CrossRefPubMed
13.
Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468–473.CrossRefPubMed
Metadata
Title
Regression of B-Cell Lymphoma of the Liver with Hepatitis C Virus Infection After Treatment with Pegylated Interferon-α and Ribavirin
Authors
Yayoi Oda
Tadayuki Kou
Masaki Watanabe
Yojiro Sakuma
Nori Taguchi
Yoko Kato
Yasushi Kudo
Atsushi Yamauchi
Yasushi Sugiura
Shinya Ohashi
Masanori Asada
Toyokazu Fukunaga
Kiyotaka Kawaguchi
Hiroaki Ito
Takefumi Nakamura
Shujiro Yazumi
Publication date
01-06-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0902-5

Other articles of this Issue 6/2010

Digestive Diseases and Sciences 6/2010 Go to the issue

Editorial

Probing the Occult: Testing for Blood in the Stools

Original Article

Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US

Case Report

Modulation of Th1/Th2 Balance by Infliximab Rescues Postoperative Occurrence of Small-Intestinal Inflammation Associated with Ulcerative Colitis

Original Article

Adenoma Development in a Patient with MUTYH-Associated Polyposis (MAP): New Insights into the Natural Course of Polyp Development

Original Article

Late Relapse of Type 1 Autoimmune Hepatitis After Corticosteroid Withdrawal

Original Article

Elevated Serum Matrix Metalloproteinase-3 and -7 in H. pylori-Related Gastric Cancer Can Be Biomarkers Correlating with a Poor Survival
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits